Read if you want one stock you can retire on

Search
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Predictive Technology Group to Present at Two Upcoming Investment Conferences



GlobeNewswire•September 21, 2018


SALT LAKE CITY, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a life-sciences technology company, announces that Bradley Robinson, President and CEO, will present a corporate update at two upcoming investment conferences:


  • LD Micro New York Conferenceon Tuesday, September 25, at 2:00 p.m. Eastern time in New York City; and

  • The MicroCap Conferenceon Monday, October 1, at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) at the Essex House in New York City. Mr. Robinson will also serve as a panelist on the “Regulatory Trends and Pricing in Biotech; CEO’s Perspective” session being held October 1 at 12:00 p.m.
A live webcast and replay of the company presentation at The MicroCap Conference will be available on the company’s website athttp://predtechgroup.com/investor-relations/.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.
Contact:
Investors
LHA Investor Relations
Jody Cainjcain@lhai.com
Kevin Mc Cabekmccabe@lhai.com
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
PRED: Early Diagnosis Can Save 1 in 10 Women




spaceball.gif


Zacks Small Cap Research
September 24, 2018





ByJohn Vandermosten, CFA



Endometriosis affects an estimated 200 million women worldwide and is frequently misdiagnosed, preventing its early and proper treatment. While most women affected by the disease are in their 20s and 30s, the first signs appear at puberty. Puberty is also the best time to begin treatment due to the progressive nature of the disorder. While it can be debilitating if not addressed, the problem does have a solution: early and accurate diagnosis. And prompt palliative treatment can prevent or delay disease progression. Failing to properly identify and treat endometriosis typically results in irreversible periodic intense pain, infertility, bowel and urinary disorders and other discomfort.

As of today, there are no lab tests available to diagnose endometriosis. This has led to misdiagnosis and the attribution of symptoms to other problems such as ovarian cysts, irritable bowel syndrome, normal monthly period pain or other conditions. As a result, patients suffer from ineffective treatment and a decline in health. A system with both an effective early-stage diagnostic and treatment may relieve symptoms and improve both the health and quality of life for a significant segment of the population.


View Exhibit I- PRED Logo

To address this unmet need, Predictive Technology Group (PRED) is developing a diagnostic test called Advanced Reproductive Therapy Guide (ARTGuide™) to test for genetic causes of infertility. ARTGuide and its companion for primary care, ENDORisk™, examine sequences in the genome that are associated with endometriosis, and along with a clinical questionnaire, can anticipate endometriosis before the symptoms can be observed.

Beyond its genetic-based diagnostics segment, Predictive’s other subsidiaries focus on women’s health, spine-related disorders and tissue collection. The company is currently producing revenues from its regenerative medicine subsidiary, Predictive Biotech. This branch maintains a core competency in human cell and tissue processing (HCT/P) and has commercialized four products: AmnioCyte™, AmnioCyte Plus™, PolyCyte™ and CoreCyte™. AmnioCyte and AmnioCyte Plus are derived from amniotic fluid and commercialized as a tissue allograft. PolyCyte and CoreCyte are derived from Wharton’s Jelly, which is found in the umbilical cord and contains high levels of proteins, cytokines, growth factors, and mesenchymal stem cells. All of Predictive’s regenerative medicine products are used by physicians to aid the body’s healing process.

Predictive’s third subsidiary is CellSure. This subsidiary procures the birth tissues used by the biotech group for its regenerative products. Its goal is to develop a bio-repository that will create a genetic library to help diagnose and anticipate disease.

Predictive Technology’s primary focus this year is on endometriosis. The company is seeking to develop a drug and a diagnostic to identify the one in ten women with endometriosis and facilitate treatment. ARTGuide will be offered as a lab developed test (LDT) while it is being commercialized into some of the top fertility centers in the United States. In conjunction with the diagnostic, the company is in discussions with other pharmaceutical companies that offer endometriosis therapies and is developing its own remedies to more effectively treat early to moderate disease progression.

Endometriosis

Endometriosis is a female condition where the tissue that lines the uterus begins to proliferate in other parts of the body. This tissue will grow and bleed in response to hormonal changes during ovulation. Women with the disorder are of menstruating age and suffer from a variety of pain related symptoms which include:

‣ Painful periods
‣ Pain in the abdomen during menstruation
‣ Heavy menstrual bleeding
‣ Infertility
‣ Pain after sexual intercourse
‣ Painful defecation

According to the American Society of Reproductive Medicine, up to 50% of women with endometriosis suffer from infertility. A similar percentage of all infertile women suffer from endometriosis.

Endometrial tissue, which normally lines the uterus, is sometimes located outside of it. Ectopic endometrial cells are most commonly found on the ovaries, fallopian tubes, and on the bowel and bladder. These cells or lesions inflame and bleed every month in response to the hormonal cycle. Estrogen and progesterone regulate the growth of endometrial tissue by stimulating and inhibiting cell proliferation. With the passage of years, scarring, inflammation and organ dislocation occur causing adhesion between areas where the ectopic endometrial tissue grows. Genetic factors are understood to contribute to the disorder.


View Exhibit II- Location of Ectopic Endometrial Tissue

Endometriosis is difficult to diagnose and can be mistaken for other conditions such as appendicitis, ovarian cysts, fibroids or a number of other disorders. Most women are diagnosed based on the symptoms presented along with a sonogram or MRI, but these results are usually inconclusive. A laparoscopy is frequently performed to provide a conclusive assessment and requires surgery and examination of the uterus and surrounding tissue. This invasive approach is costly and unpleasant.

Genetics plays a role in endometriosis. Studies have shown that sisters, mothers and daughters of those affected are 5 to 7 times more likely to have the disease. Additional work has been performed to identify a genetic signature for predisposed women. While there is no cure, there is treatment for endometriosis which can include surgery, hormones and the use of painkillers. The combination of birth control and NSAIDs is one common approach and in more serious circumstances laparotomy or hysterectomy may be performed. If taken early, hormone treatments can prevent the endometrial tissue from proliferating and limit the damage. The hormones can inhibit ovulation and reduce estrogen levels. Progesterone specifically can decrease the activity of estrogen receptors, which has several beneficial effects on the disease through growth inhibition of endometrial tissue as well as reducing blood vessel growth, reduction of inflammation and moderation of the menstrual cycle.

New Treatment

Abbvie’s elagolix is a new treatment for the disease which was approved by the FDA this July. It is based on a gonadotropin-releasing hormone (GnRH) receptor agonist which binds competitively to the GnRH receptors on the pituitary gland. Elagolix has been effective in reducing pelvic pain related to endometriosis; however, there are serious side effects associated with bone loss and the drug can only be used for up to two years at the lower dose and six months at the higher dose. Other side effects are similar to those suffered in menopause and include hot flashes, amenorrhea, headaches and nausea. Given its limitations, elagolix is not a long-term solution for endometriosis and there is demand for something better. Despite elagolix’s shortcomings, Abbvie sees a market in excess of $2 billion for the drug, which includes contributions from a fibroid indication.

Other treatments in development for endometriosis include Myovant’s Relugolix and Obseva’s Linzagolix. Both of these are in the same class as Abbvie’s drug: GnRH receptor agonists. These agonists are used in a variety of diseases including breast cancer, prostate cancer, uterine fibroids and female infertility with the best known example called Lupron. Natural GnRH is produced by neurons in the hypothalamus, but has an antagonistic effect. Therefore, this class of drug will compete with the natural GnRH for binding to GnRH receptors, which can decrease or block the production of the hormone. By inhibiting GnRH receptors, the drugs reduce the circulating gonadotropins luteinizing hormone and follicle stimulating hormone, leading to the suppression of sex hormones. Relugolix underwent a Phase II clinical trial in 487 patients with endometriosis and now Myovant is currently advancing it through a Phase III clinical study. Linzagolix is currently being studied in a Phase IIa trial for endometriosis in the US and Europe. A Phase 2b is expected soon.

Diagnostics

The approved and in-development products for endometriosis are good news for Predictive. The ARTGuide test assists in-vitro fertilization (IVF) specialists and patents in determining the optimal course of care for fertility treatment, accounting for the effects of endometriosis and other genetic causes of fertility. ENDORisk is focused on identifying patients at a high risk for endometriosis and can guide the prescription of one of the FDA-approved treatments available. The current timeline calls for ARTGuide to be available for patients before year-end as a non-invasive test for endometriosis and other genetic causes for infertility. The tests were developed using data from over 30,000 endometriosis patients and over 100,000 genetically sequenced population controls to identify relevant markers. Validation of the markers was conducted through two genome wide association studies (GWAS) that paired genome variants with the presence of endometriosis and sequenced 3,000 exomes to detect low frequency variants. Over 1,000 markers were identified and patented for development. The results of ARTGuide will be combined with clinical observations of the patients to produce a 90%+ positive identification rate. While the company has not disclosed what they will charge, the cost to run the test is estimated to be less than $100, suggesting that they can be very competitive in the mass market to identify likely cases.

Apart from a laparoscopy which is invasive and may cost from $8 to $20 thousand per procedure, there are no tools to diagnose early stage endometriosis. The lack of an inexpensive and non-invasive test has left many women undiagnosed and a large population with an unmet need. Following the launch of ARTGuide, we anticipate that Predictive Therapeutics will seek out partnerships with the large pharmaceutical companies offering endometriosis therapies to the non-infertility markets. We highlight the importance of having an effective diagnostic tool for any disease that can be easily misdiagnosed. The lack of a proper evaluation can result in a patient being denied timely treatment or being given potentially toxic and improper medications.

The ability to accurately diagnose women with the disorder is critical for treating the population with the unmet need. It is also important from a payor’s perspective and can improve the likelihood of formulary inclusion. Payors value a diagnostic test that can identify the appropriate population for treatment, as they are only providing medicine for patients that will respond, resulting in lower but more appropriate usage and better outcomes.

Company Strategy

Predictive’s plan to launch ENDORisk is expected to be followed by a treatment option. The company is planning to develop a pipeline of therapies from both internal efforts and external partnerships to treat early to advanced stages of the disease. One potential therapy being pursued is a combination of progesterone/progestin with a non-steroidal anti-inflammatory. This combination of medicines is the most commonly prescribed therapy for endometriosis, and is effective especially when it is caught early. While the precise formulation of the two medications that Predictive will use has not yet been decided, the company will focus on options that have substantial safety data available and that have been previously approved by the FDA. Approval for this therapy will likely be sought via the 505(b)(2) pathway. Management has publically indicated that it could take 18 months and $15 million to pursue this route; however, based on our experience with combinations of well-understood chemical entities, approval could come in about a year and with the use of less expensive bridging studies.

The strategy for commercialization of ARTGuide is to target the top ten metropolitan areas for infertility services and offer it in these high volume areas. Over the last couple decades, infertility services have gravitated towards centers of excellence in a few major metropolitan areas, and patients have been willing and able to travel to locations with the best reputations. This concentration of fertility clinics has made it efficient for companies with fertility and women’s health products to communicate and educate providers about their value. Predictive believes it can effectively develop the ARTGuide and FertilityDx™ line of diagnostics with an eight to ten person salesforce and effectively penetrate 80% of the United States market.

To discover the potential for a diagnostic test in the infertility markets, Predictive commissioned a study targeting infertility specialists to gauge interest in prescribing ARTGuide. It found that there was significant interest in the test and a third of the physician respondents would offer the test to all of their new patients on their first visit. Based on company estimates assuming penetration into just 12 of 480 US clinics, each with nine physicians, ARTGuide and Fertility Dx could generate over $150 million in revenues.

Summary

Predictive Technologies is an emerging company currently focused on diagnosing and ameliorating endometriosis in millions of women. The company is also an important contributor to the regenerative medicine market with four products producing revenues at an annual run rate of near $30 million. With Predictive Biotech’s past success in developing a sales force, there is reason to believe that ARTGuide and FertilityDx can be rapidly and successfully rolled out to existing targeted and concentrated markets. Partnership opportunities with big pharma companies that offer endometriosis treatments can be mutually beneficial as it will allow for identification of those with the disease and incentivize treatment. Certainty of diagnosis from an affordable and easily administrated test can improve penetration and encourage payors to offer the appropriate treatment. Predictive is in an enviable position with the imminent launch of the only non-invasive diagnostic for endometriosis and can see additional benefit when they ultimately launch companion treatments.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.

___________________________________

1.Endometriosis Foundation of America.
2.The Practice Committee of the American Society for Reproductive Medicine. "Endometriosis and infertility:
a committee opinion."
3.Hummelshoj, L. (n.d.). "Adhesions." Endometriosis.org.
4. Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014." WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436
5.Clin Obstet Gynecol. (2010) "Genetics and Genomics of Endometriosis." PMC 2015 Mar 2. DOI: 10.1097/GRF.0b013e3181db7ca1.
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Predictive Technology Group Acquires Inception Dx

GlobeNewswire•September 25, 2018



SALT LAKE CITY, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that it has acquired Inception Dx. Inception Dx will operate as a wholly owned subsidiary of Predictive Technology Group.

The acquisition of Utah-based Inception Dx includes next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA).
“We are excited to offer next-generation sequencing and genotyping that will allow Predictive Technology Group to further leverage and accelerate the commercialization of diagnostics and therapeutics from our unique development platforms,” said Bradley Robinson, CEO of Predictive Technology Group.
Predictive Diagnostics will launch ARTGuide™, a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, during fourth quarter of 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such asin vitrofertilization (IVF), are used to assist couples having difficulty conceiving. Over 30,000 DNA samples and medical records have been collected as part of the development and validation process of ARTGuide™.
About Endometriosis:
Approximately 27 million women in the United States are symptomatic of endometriosis. Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman's quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.
Contact:
Investors
LHA Investor Relations
Jody Cainjcain@lhai.com
Kevin Mc Cabekmccabe@lhai.com
310-691-7100
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Predictive Technology Group Acquires Key DNA and Ancestry Assets





GlobeNewswire•October 2, 201





SALT LAKE CITY, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that it has acquired DNA and ancestry assets, including significant genetic data related to women’s diseases and degenerative disc disease from Taueret Laboratories, LLC.

The acquired assets include: (i) approximately 1,000 degenerative disc disease-related DNA samples, related family records, relevant clinical records (including approximately 600 affected probands) and 800 ancestry matched control samples, (ii) whole exome sequencing data on approximately 300 degenerative disc disease samples, over 800 local controls, and published reference populations, together with initial analysis of the markers, and (iii) exclusive use of a DNA biobank that has collected over 300,000 samples for multiple diseases that the Company may target.
“Although our focus remains on endometriosis, the acquisition of these key DNA and ancestry assets significantly strengthens our development platforms to commercialize gene-based diagnostics and biotechnology treatments for other debilitating diseases, such as additional difficult-to-diagnose women’s health diseases and degenerative disc disease,” said Bradley Robinson, CEO of Predictive Technology Group. “These assets are complementary to our recent acquisition of Inception Dx, which included ancestry database records for over 31.9 million individuals for use in genetics research. With Inception Dx, we are now positioned to further develop the assets acquired from Taueret Laboratories.”
About Endometriosis:
Approximately 27 million women in the United States are symptomatic of endometriosis. Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman's quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cainjcain@lhai.com
Kevin Mc Cabekmccabe@lhai.com
310-691-7100
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Predictive Diagnostics Launches Endometriosis Risk Test


GlobeNewswire•October 4, 2018



SALT LAKE CITY, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of data analytics for disease identification enabling revolutionary therapeutic approaches, announces that its subsidiary, Predictive Diagnostics, will launch a unique endometriosis risk test this weekend at the 74[SUP]th[/SUP]American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo in Denver, Colorado.
The test, ARTguide™, is a first-in-class non-invasive diagnostic test for endometriosis and other genetic causes of infertility. ARTguide™ is indicated for the hundreds of thousands of women considering use of Assisted Reproductive Technologies (ART) such as In Vitro Fertilization (commonly referred to as IVF). Next generation sequencers will be used to test the patient for variants in 11 genes known to impact human fertility. Additionally, over 750 DNA markers associated with endometriosis are tested using a proprietary algorithm. The test was developed using tens of thousands of patient samples and billions of analyzed genotypes.
“I am confident that the ARTguide™ test will help couples challenged with infertility to have healthy babies transforming the lucrative assisted reproductive technology market,” said Bradley Robinson, CEO of Predictive Technology Group. “ARTguide™ will provide ‘must-have’ information for couples and their physicians selecting an optimal course of care.”
Predictive Diagnostics was recently created through strategic acquisitions and will process ARTguide™ in its recently acquired CLIA laboratory in Salt Lake City, Utah. Predictive Diagnostics will launch ARTguide™, in six beta sites over the next few months, and the test will be made available to the entire US infertility market in the second quarter of 2019.
About Endometriosis:
Approximately 27 million women in the United States are symptomatic of endometriosis. Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman's quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Juneau Biosciences Presents New Genetic Discoveries in Endometriosis at ASRM Scientific Congress & Expo



GlobeNewswire•October 9, 2018



SALT LAKE CITY, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED) (“Predictive”), reports that Kenneth Ward, M.D., CEO of Juneau Biosciences, LLC, presented new scientific discoveries concerning the genetics of endometriosis at the 74[SUP]th[/SUP]American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo underway in Denver, Colo. Juneau Biosciences is a majority-owned subsidiary of Predictive.

Dr. Ward’s paper, entitled “Can Genetic Markers of Endometriosis Predict a Patient’s Responsiveness to Leuprolide Acetate,” addresses the impact genes underlying endometriosis have on the degree of relief a patient receives when prescribed leuprolide acetate, the most widely used FDA-approved therapy for endometriosis. Dr. Ward’s paper was recognized with the ASRM Scientific Program Committee’s “Best in Clinical/Population Science Prize Paper” research award.
On October 10 representatives from Juneau will make three additional scientific presentations based on data from Predictive’s Genealogy Database (GenDB™), exploring the use of extended family trees in disease gene discovery. Two of these presentations examine the lineage of families with the largest presence of genes linked to endometriosis reported to date. One family tree spans 19 generations and includes over 250 women living with surgically-confirmed endometriosis, all descendants of a man born in 1608. Data from GenDB suggests that more than 1 million women in the United States may carry this family’s risk factor.
“Predictive is using its powerful GenDB™ database to increase the efficiency and thoroughness of gene discoveries in complex diseases,” said Bradley Robinson, CEO of Predictive Technology Group. “As Predictive scales its genomics and artificial intelligence capabilities, our objective is to transform the diagnosis, prediction and treatment of common diseases that lead to tremendous human suffering.”
Predictive and Juneau have employed state-of-the-art genomic methods to uncover hundreds of genes that play a role in endometriosis development and progression. The companies’ population genetics research underlies the novel ARTGuide™ test, a first-of-its-kind non-invasive diagnostic test for endometriosis and other genetic causes of infertility, recently launched by Predictive subsidiary Predictive Diagnostics.
ASRM is an international and multi-disciplinary organization devoted to advancing knowledge and expertise in reproductive medicine and biology, with a particular focus on human infertility.
About Endometriosis:
Approximately 27 million women in the United States are symptomatic of endometriosis. Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman's quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics, Predictive Diagnostics, and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
SALT LAKE CITY, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that it has acquired Regenerative Medical Technologies, Inc. (RMT). The acquisition includes an allogeneic stem cell product design, intellectual property, access to data and medical records from patients in 13 clinics, and clinical trial methodology for degenerative disc disease (DDD).

Concurrent with the acquisition of RMT, Rick Obray, M.D. joins as Chairman of the Predictive Clinical Advisory Board. Dr. Obray received his Doctor of Medicine degree from Johns Hopkins University School of Medicine. After completing a spine and musculoskeletal fellowship at Johns Hopkins, Dr. Obray completed an interventional pain fellowship at Mayo Clinic, making him one of the few physicians in the country to complete fellowship training and receive board certifications in both pain medicine and diagnostic imaging. Dr. Obray also currently serves as the director of Spine and Pain Medicine at Intermountain Health Care’s Dixie Regional Medical Center.
“We are pleased to complete the RMT acquisition and welcome Dr. Obray to the Predicitive team as we expand our clinical expertise and further advance Predictive’s DDD development platform,” said Bradley Robinson, CEO of Predictive Technology Group. “With his expertise and clinical experience, Dr. Obray provides insight into the latest in spinal care and treatment, clinical research, and real world perspective to multidisciplinary care for patients. As translational medicine is a highly interdisciplinary field, Dr. Obray’s experience brings tremendous value to Predictive in addressing both patient needs for new and more effective precision therapies while addressing concerns of all stake holders in healthcare.”
Dr. Obray stated, “It has been my longtime ambition to provide relief to patients through revolutionary approaches utilizing precision medicine. I am very excited to join the Predictive team in bringing disruptive technology and new treatment options to those suffering from degenerative disc disease.”
About Degenerative Disc Disease
Low back pain is a leading health problem, affecting 266 million individuals worldwide. It is one of the most prevalent reasons for a doctor’s visit, behind only the common cold. Billions of dollars are spent annually on treating degenerative disc disease, which is the most typical cause of back pain. More than 90% of people will experience an episode of debilitating back pain at some point in their lifetime.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Predictive Technology Group Appoints Charles Andres to Its Scientific Advisory Board



GlobeNewswire•October 18, 2018





SALT LAKE CITY, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces the appointment of Charles Andres, J.D., Ph.D., RAC, HBX CORe, to its Scientific Advisory Board.

As an attorney at Wilson Sonsini Goodrich & Rosati (WSGR), Mr. Andres leads the life sciences group in that firm’s Washington DC office. He represents a broad range of companies, including those at the forefront of cellular therapy, regenerative medicine, diagnostics, and immuno-oncology. His practice encompasses intellectual property, FDA/regulatory, transactional, business, and governmental matters. Prior to becoming a patent professional, Mr. Andres spent a decade as a medicinal chemist and early-phase project co-chair at Bristol-Myers Squibb Company, where he won a Presidential Award among other accolades. He holds Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society.
“We are very pleased to have Charlie join our Scientific Advisory Board,” said Bradley Robinson, CEO of Predictive Technology Group. “In additional to advising Predictive on IP matters, Charlie has made significant contributions to Predictive in its strategic and business development activities and transactions. Having Charlie sit as a member of the Predictive Scientific Advisory Board will be of great strategic benefit to our Company.”
“I am excited to join the Scientific Advisory Board of Predictive and to work with the Company’s cutting-edge technologies to improve the lives of patients suffering from chronic diseases,” said Mr. Andres. “I look forward to helping Predictive fulfill its mission of changing patients’ lives through novel disease diagnostics and subsequent therapeutic intervention by leveraging its unique and proprietary development platforms.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.
 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Predictive Technology Group Appoints Industry Veteran John E. Sorrentino as Chairman





GlobeNewswire•October 30, 2018


Sorrentino Expands Role to Support Goal of Bringing Innovative Technologies to MarketSALT LAKE CITY , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that John E. Sorrentino has been named Chairman of the Board in addition to his role as Chair of the Predictive Scientific Advisory Board. Sorrentino has more than 35 years of senior management experience in the life sciences industry and serves as Vice President and Chief Operating Officer of Pfizer Vaccine Research and Development. He replaced Merle Ferguson, who will continue as a Director of the Company.
Sorrentino brings vast experience in R&D, commercialization and clinical laboratory management and has served in leadership positions in public and private companies. Prior to joining Wyeth/Pfizer 15 years ago, he held executive positions in several organizations that provided neonatal screening and related clinical services. Sorrentino is a noted expert in the healthcare industry, having presented to state legislatures, the U.S. Congress and professional societies on a variety of healthcare and policy issues.
“We are pleased to have John expand his involvement at our Company’s most senior level, as we introduce our first endometriosis risk test, ARTguide™,” said Bradley C. Robinson, CEO of Predictive Technology Group. “John's experience, commitment and passion to delivering improved, more comprehensive healthcare to patients will be of tremendous assistance in ensuring Predictive delivers on our mission of preventing or eliminating disease for generations to come. We thank Merle for serving as Chairman and are delighted he will continue to serve as a Board member.”
“We could not have found a more qualified and committed individual to serve as Chairman and lead the company’s corporate governance,” said Ferguson. “As a longtime friend, I have seen first-hand John’s commitment to improving healthcare. I look forward to his guidance as Predictive advances cutting-edge technologies to commercialization and we seek to list our securities on a national exchange.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.





 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
Predictive Technology Group to Present at 11th Annual LD Micro Main Event Conference on December 4


GlobeNewswire•November 27, 2018



SALT LAKE CITY, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a life-sciences technology company, announces that Bradley Robinson, President and CEO, will present a corporate update at the 11[SUP]th[/SUP]Annual LD Micro Main Event Conference on Tuesday, December 4, 2018 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.

A live webcast and replay of the presentation will be available on the events section of the Company’s website atwww.predtechgroup.com/investor-relations.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.
Contact:
Investors
LHA Investor Relations
Jody Cainjcain@lhai.com
Kevin Mc Cabekmccabe@lhai.com
310-691-7100







 
brucefan

brucefan

Member
Joined
Jan 19, 2005
Messages
3,255
Tokens
brucefan said:
Predictive Technology Group to Present at 11th Annual LD Micro Main Event Conference on December 4


GlobeNewswire•November 27, 2018



SALT LAKE CITY, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a life-sciences technology company, announces that Bradley Robinson, President and CEO, will present a corporate update at the 11[SUP]th[/SUP]Annual LD Micro Main Event Conference on Tuesday, December 4, 2018 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.

A live webcast and replay of the presentation will be available on the events section of the Company’s website atwww.predtechgroup.com/investor-relations.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available atPredtechgroup.com;Predrx.comandPredictivebiotech.com.
Contact:
Investors
LHA Investor Relations
Jody Cainjcain@lhai.com
Kevin Mc Cabekmccabe@lhai.com
310-691-7100
Click to expand...

http://predtechgroup.com/wp-content/uploads/2018/12/PRED-Overview-Presentation-12-4-18-BCR-V5.pdf
 

halekulani

New member
Joined
Jan 4, 2007
Messages
5,985
Tokens
some otc stock is going to compete against the likes of merck? nah dont think so

diagnostics is from this group is not going to play a role in standard of care or be first line
 
MattyMatt

MattyMatt

Member
Handicapper
Joined
Jan 16, 2010
Messages
17,864
Tokens
Really enjoyed this little ride up on PRED here lately. Bought all I could at $1, and snagged a little more at $1.18. Hopefully we’re just getting started. Looks like it may be a quick ride, too...

Tempted to buy a little more at the current levels...
 
You must log in or register to reply here.

Forum statistics

Threads
1,118,682
Messages
13,558,263
Members
100,668
Latest member
willsonjames480

Share this page

The RX is the sports betting industry's leading information portal for bonuses, picks, and sportsbook reviews. Find the best deals offered by a sportsbook in your state and browse our free picks section.FacebookTwitterInstagramContact Usforum@therx.com
@2023 TheRX. All rights reserved.21+. Bet Responsibly: If you or someone you know has a gambling problem, seek help at 1-800-Gambler